Skip to main content

Table 1 Baseline characteristics of study population in 10 trials

From: Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies

Study/author

Public year

Country

Age (year)

Total (I/C)*

Female (%)

follow-up years

Medications used (I/C)*

BP (mmHg) I(SBP/DBP; C(SBP/DBP

Reduction of BP (mmHg)#I(SBP/DBP; C(SBP/DBP)

UKPDS [19]

1998

United Kingdom

56

400/358

48

over 9

Captopril/Atenolol

159/94; 159/93

15/10; 16/12

FACET [11]

1998

United State

63

189/191

41

2.5-3.5

Fosinopril/Amlodipine

170/95; 171/94

19/8; 13/8

RENAAL [23]

2001

Multi-centers

60

751/762

37

3.4

Losartan/Placebo

152/82; 153/82

12/8; 11/8

CAPPP [12]

2001

Sweden/Finland

25–66

309/263

38

6.1

Captopril/Conventional drugs

164/97; 163/97

8/4; 10/5

IDNT [14, 17]&

2001/2003

Multi-centers

30-70

579/569

32

2.6

Irbesartan/Placebo

160/87; 158/87

20/10; 16/7

ADVANCE [13]

2007

Multi-centers

66

5,569/5,571

43

4.3

Perindopril/Placebo

145/81; 145/81

5.6/2.2#

CASE-J [21]

2010

Japan

64

1,011/1,077

44

3.3

Candesartan/Amlodipine

160/88; 160/88

---

DEMAND [20]

2011

Italy/Slovenia

≥40

127/127

37

3.8

Delapril/Placebo

147/87; 147/88

11/6; 9/5

NHS [22]

2012

Japan

63

575/575

34

3.2

Valsartan/Amlodipine

145/82; 144/81

14/9; 13/8

  1. UKPDS = United Kingdom Prospective Diabetes Study Group, FACET = Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial, RENAAL = Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan, CAPPP = The Captopril Prevention Project, IDNT = Irbesartan Diabetic Nephropathy Trial, ADVANCE = The Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation, CASE-J = candesartan antihypertensive survival evaluation in Japan, DEMAND = Delapril and Manidipine for Nephroprotection in Diabetes, NHS = NAGOYA HEART Study.
  2. *I/C = Intervention/Control, SBP = systolic blood pressure, DBP = diastolic blood pressure; #reduction of SBP/DBP in intervention group compared with in placebo; ----- not give detail information; &IDNT data was used in two articles for the analysis of different endpoint events.